Effects of Major Liver Resection, With or Without Recombinant Bactericidal/Permeability-Increasing Protein (rBPI21), on the Angiogenic Profile of Patients With Metastatic Colorectal Carcinoma

Journal of Surgical Oncology

Volumn 84, Issue 3, 2003, Pages 137-142

  Wu, Francis P K ^a   Boelens, Petra G ^a   Van Leeuwen, Paul A M ^a   Hoekman, Klaas ^a   Hansma, Annemarie H G ^a   Wiezer, Marinus J ^a   Meijer, Catharina ^a   Meijer, Sybren ^a   Scotté, Michel ^b   Cuesta, Miguel A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Angiogenesis; Endostatin; Interleukin 6; Liver resection; Recombinant bactericidal permeability increasing protein (rBPI21); VEGF

Indexed keywords

CYTOKINE; ENDOSTATIN; INTERLEUKIN 6; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INTRAOPERATIVE PERIOD; LEUKOCYTE COUNT; LIVER METASTASIS; LIVER SURGERY; MALE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECTUM RESECTION; THROMBOCYTE COUNT; WOUND HEALING;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; ENDOSTATINS; FEMALE; HEPATECTOMY; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0242266898     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10307     Document Type: Article

References (34)

1. Butler J, Attiyeh FF, Daly JM: Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986;162:109-113.
2. Nagasue N, Kohno H, Chang YC, et al.: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993;217:375-384.
3. Finch MD, Crosbie JL, Currie E, et al.: An 8 year experience of hepatic resection: Indications and outcome. Br J Surg 1998;85:315-319.
4. Shirabe K, Shimada M, Gion T, et al.: Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999;188:304-309.
5. Pace RF, Blenkharn JI, Edwards WJ, et al.: Intra-abdominal sepsis after hepatic resection. Ann Surg 1989;209:302-306.
6. Wiezer MJ, Boelens PG, Vuylsteke RJ, et al.: Perioperative treatment with bactericidal/permeability-increasing protein (rBPI21) in major liver surgery: A concise summary. Ann Acad Med Singapore 2001;30:226-233.
7. Marra MN, Wilde CG, Griffith JE, et al.: Bactericidal permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990;144:662-666.
8. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992;90:1122-1130.
9. van der Schaft DW, Toebes EA, Haseman JR, et al.: Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000;96:176-181.
10. Cohen T, Nahari D, Cerem LW, et al.: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-741.
11. Cressman DE, Greenbaum LE, DeAngelis RA, et al.: Liver failure and defective hepatocyte regeneration in interleukin-6 deficient mice. Science 1996;274:1379-1383.
12. Neufeld G, Cohen T, Gengrinovitch S, et al.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
13. Maniwa Y, Okada M, Ishii N, et al.: Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114:1668-1675.
14. Bondestam J, Salven P, Jaaskela-Saari H, et al.: Major surgery increases serum levels of vascular endothelial growth factor only temporarily. Am J Surg 2000;179:57-59.
15. Salven P, Orpana A, Joensuu H: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5:487-491.
16. Mateo RB, Reichner JS, Albina JE: Interleukin-6 activity in wounds. Am J Physiol 1994;266:R1840-R1844.
17. Mochida S, Ishikawa K, Inao M, et al.: Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. Biochem Biophys Res Commun 1996;226:176-179.
18. Taniguchi E, Sakisaka S, Matsuo K, et al.: Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 2001;49:121-130.
19. Dhanabal M, Ramchandran R, Waterman MJ, et al.: Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-11726.
20. Yoon SS, Eto H, Lin CM, et al.: Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251-6256.
21. Wen W, Moses MA, Wiederschain D, et al.: The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6056.
22. Felbor U, Dreier L, Bryant RA, et al.: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-1194.
23. Muragaki Y, Timmons S, Griffith CM, et al.: Mouse Co118a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA 1995;92:8763-8767.
24. Schuppan D, Cramer T, Bauer M, et al.: Hepatocytes as a source of collagen type XVIII endostatin. Lancet 1998;352:879-880.
25. Wiezer MJ, Meijer C, Sietses C, et al.: Bactericidal/permeability-increasing protein preserves leukocyte functions after major liver resection. Ann Surg 2000;232:208-215.
26. Meszaros K, Parent JB, Gazzano-Santoro H, et al.: A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS. J Leukoc Biol 1993;54:558-563.
27. 21) after liver surgery in rats and humans. Shock 1998;10:161-166.
28. Boermeester MA, Houdijk AP, Meyer S, et al.: Liver failure induces a systemic inflammatory response. Prevention by recombinant N-terminal bactericidal/permeability increasing protein. Am J Pathol 1995;147:1428-1440.
29. Yamane A, Seetharam L, Yamaguchi S, et al.: A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994;9:2683-2690.
30. Fujisaki K, Mitsuyama K, Toyonaga A, et al.: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998;93:249-252.
31. Keppler D, Waridel P, Abrahamson M, et al.: Latency of cathepsin B secreted by human colon carcinoma cells is not linked to secretion of cystatin C and is relieved by neutrophil elastase. Biochim Biophys Acta 1994;1226:117-125.
32. Bjornland K, Buo L, Scott H, et al.: Polymorphonuclear elastase in human colorectal carcinoma. Int J Oncol 1998;12:535-540.
33. Thomas JP, Arzoomanian RZ, Alberti D, et al.: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-231.
34. O'Reilly MS, Holmgren L, Shing Y, et al.: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.